Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science. That capital is not spreading evenly: it is concentrating on precision medicine, where the global oncology precision medicine market is projected to reach $303 billion by 2035[2], growing at approximately 9% annually as targeted cancer treatments move from promising idea to standard care. The five companies in thi
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's pipelineSEATTLE, March 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare diseases, today announces the engagement of Kathy Puyana Theall, M.D., as Medical Director - Breast Oncology, and Adebola Giwa, M.D., as Medical Director - Rare Diseases. The addition of these two highly experienced physicians and clinical leaders meaningfully strengthens Atossa's ability to execute on its (Z)-endo
Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic MiceSEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need, presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL. Presentation HighlightsThe mdx5Cv Dystrophic mouse model, a trusted
4/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
424B5 - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
424B3 - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's pipelineSEATTLE, March 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare diseases, today announces the engagement of Kathy Puyana Theall, M.D., as Medical Director - Breast Oncology, and Adebola Giwa, M.D., as Medical Director - Rare Diseases. The addition of these two highly experienced physicians and clinical leaders meaningfully strengthens Atossa's ability to execute on its (Z)-endo
SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows: To our valued shareholders, In looking back on 2025, Atossa made meaningful progress advancing proprietary oral (Z)-en
25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE, Oct. 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science
FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE, Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments. "Atos
Announced strategic plan to advance (Z)-endoxifen for metastatic breast cancer indication Enhanced (Z)-endoxifen intellectual property portfolio with three new U.S. patents, expanding IP portfolio to more than 200 patent claims related to (Z)-endoxifen Ended first quarter 2025 with $65.1 million in cash and cash equivalents and no debt SEATTLE, May 13, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the first quarter ended March 31, 2025 and provided an update on recent company developments.
Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre
SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)